You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. CATHEPSIN L INHIBITORS AS PAN CORONAVIRUS THERAPEUTICS

    SBC: PHELIX THERAPEUTICS LLC            Topic: R

    DESCRIPTION provided by applicant Coronaviruses CoV are RNA viruses that cause gastrointestinal respiratory and neurological symptoms in several mammalian species The outbreak of the severe acute respiratory syndrome CoV SARS CoV in humans was fatal in of infected patients infecting people and killing The recent incidents involving the highly pathogenic Middle East ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  2. CAD-CAM Technology for Diabetic Footwear

    SBC: DIAPEDIA, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Diabetes remains the leading cause of non-traumatic lower extremity amputations. Most amputations are preceded by a foot ulcer, so that successfully treating, or better still preventing, foot ulcers should reduce the n umber of diabetes related amputations. The majority of foot ulcers in diabetic patients are the result of loss of protective sensation (LOPS) s ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  3. Development of Small Molecule Therapeutics Against Smallpox and Other Poxviruses

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: R

    DESCRIPTION provided by applicant The smallpox virus variola has been responsible for the deaths of hundreds of millions of people worldwide Although smallpox was eradicated from the globe in following a valiant immunization campaign existing viral stocks may fall into the hands of those seeking to employ variola as a biological weapon This calls for the development of safe antiviral ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Clinical Investigation of the Ceramide NanoLiposome for Advanced Solid Tumors

    SBC: KEYSTONE NANO, INC.            Topic: 102

    DESCRIPTIONprovided by applicantKeystone Nanoin partnership with the University of Maryland Greenebaum Cancer CenterUMD GCCproposes a multi site clinical evaluation of the Ceramide NanoLiposomeCNLas a novel anti cancer therapeuticThe overall objective of this project is to advance the CNL through a Phase I clinical trialThe results of this trial will support subsequent trials for the intended init ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Remote Brief Intervention and Referral to Treatment Service for Alcohol (R-BIRT)

    SBC: POLARIS HEALTH DIRECTIONS, INC            Topic: NIAAA

    DESCRIPTIONprovided by applicantSignificanceThe USPHSTFSAMHSACDCand NIAAA have affirmed the importance of screening in medical settings for alcohol consumption that exceeds the NIAAA low risk limitsbrief educational and motivational counseling for those who screen positive or have other evidence of an Alcohol Use Disorderandwhen appropriatereferral to treatmentSBIRTHowevertranslation to clinical p ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Clinical Trial of ABC in Patients with Refractory Multiple Myeloma

    SBC: Apogee Biotechnology Corporation            Topic: NCI

    DESCRIPTION provided by applicant Multiple myeloma MM is the second most common hematological malignancy in the United States and remains an incurable disease since nearly all MM patients will eventually relapse and develop resistance to currently available drugs Sphingolipid metabolism is being increasingly recognized as a key pathway in tumor biology In particular sphingosine kinases S ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  7. A novel diagnostic biomarker for Hepatocellular Carcinoma(HCC)

    SBC: ImCare Biotech LLC            Topic: NCI

    DESCRIPTIONprovided by applicantHepatocellular carcinomaHCCis usually undetected until its later stageswhere theyear survival rate for patients is less thanHoweverthe survival rate can be as high asif the cancer is detected earlyUnfortunatelyearly detection of HCC is not possible with any screening tests that are currently availablesuch as ultrasound or imaging technologiesAlpha FetoproteinAFPwhic ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Biocompatible Coating for Pediatric Blood Oxygenators- Phase II

    SBC: ENSION Inc            Topic: N/A

    DESCRIPTION (provided by applicant): Many oxygenators clinically available for pediatric (and adult) extracorporeal membrane oxygenation (ECMO) utilize heparin coatings such as Carmeda BioActive Surface on device surfaces, including the microporous hollow fibers, to improve biocompatibility. Despite application of these coatings, significant inflammatory and coagulation-related complications, as ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  9. Sprayable Surgical Adhesive for Seroma Prevention

    SBC: COHERA MEDICAL, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The long-term goal of this project is to create a sprayable surgical adhesive which would satisfy the surgical need for a strong, easy-to-use adhesive to adhere planar flaps of tissue. This novel adhesive will reduce fl uid accumulation after surgery by eliminating dead space in the wound and maintaining tissues in position for natural healing to occur. Seroma ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  10. Polaris Oncology Survivor Transition POST System

    SBC: POLARIS HEALTH DIRECTIONS, INC            Topic: 100

    DESCRIPTION provided by applicant By January oncology care providers will be expected to craft Survivorship Care Plans SCPs for all individuals ending active treatment for cancer however there is a lack of systematic study of the impact survivorship planning has on patients providers or healthcare systems The Polaris Oncology Survivorship Transition POST program is a web based sy ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government